Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Cyclophosphamide 48fludarabine 32Methotrexate 24blinatumomab 20fludarabine phosphate 19Dexamethasone 19Vincristine 18Whole-Body Irradiation 16Specimen Handling 16Cytarabine 16Tacrolimus 14Mycophenolic Acid 14Peripheral Blood Stem Cell Transplantation 13Melphalan 13Mercaptopurine 12Calcium Dobesilate 12merphos 11Busulfan 11Biopsy 11Magnetic Resonance Spectroscopy 10Etoposide 10Stem Cell Transplantation 9Prednisone 9Granulocyte Colony-Stimulating Factor 9Cyclosporine 9Thiotepa 8Rituximab 8Mesna 8Filgrastim 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Lymphatic Irradiation × 90 days × Clear all
NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06195891 2026-04-29

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
33 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡